Butyrate-producing bacteria supplemented in vitro to Crohn’s disease patient microbiota increased butyrate production and enhanced intestinal epithelial barrier integrity

Abstract

The management of the dysbiosed gut microbiota in inflammatory bowel diseases (IBD) is gaining more attention as a novel target to control this disease. Probiotic treatment with butyrate-producing bacteria has therapeutic potential since these bacteria are depleted in IBD patients and butyrate has beneficial effects on epithelial barrier function and overall gut health. However, studies assessing the effect of probiotic supplementation on microbe-microbe and host-microbe interactions are rare. In this study, butyrate-producing bacteria (three mono-species and one multispecies mix) were supplemented to the fecal microbial communities of ten Crohn’s disease (CD) patients in an in vitro system simulating the mucus- and lumen-associated microbiota. Effects of supplementation in short-chain fatty acid levels, bacterial colonization of mucus environment and intestinal epithelial barrier function were evaluated. Treatment with F. prausnitzii and the mix of six butyrate-producers significantly increased the butyrate production by 5–11 mol%, and colonization capacity in mucus- and lumen-associated CD microbiota. Treatments with B. pullicaecorum 25-3T and the mix of six butyrate-producers improved epithelial barrier integrity in vitro. This study provides proof-of-concept data for the therapeutic potential of butyrate-producing bacteria in CD and supports the future preclinical development of a probiotic product containing butyrate-producing species.

Faecalibacterium prausnitzii‐derived microbial anti‐inflammatory molecule regulates intestinal integrity in diabetes mellitus mice via modulating tight junction protein expression

“…Faecalibacterium prausnitzii ( F. prausnitzii ) are the predominant butyrate‐producing bacteria in the gastrointestinal tract. Studies have revealed that F. prausnitzii are critical in host health and in many diseases …”

“…Studies have revealed that F. prausnitzii are critical in host health and in many diseases. [18][19][20] Metabolites from F. prausnitzii culture supernatant possess beneficial effects in inflammatory bowel disease (IBD). 21 Recently, a protein produced by F. prausnitzii called microbial anti-inflammatory molecule (MAM) was identified.…”

BowSaw: inferring higher-order trait interactions associated with complex biological phenotypes

“…Of the five associated taxa, we 497 suspect that the absence of lachnospira, lachnospiracea UCG 001, and tyzzerella are 498 biologically meaningful. We have reason to believe so because it has been reported that 499 the lachnospiraceae family is generally suppressed in Crohn's disease [32][33][34]. 500…”

Alzheimer's disease and symbiotic microbiota: an evolutionary medicine perspective

“…Gut dysbiosis may compromise barrier integrity, which may promote AD pathogenesis by allowing translocation of pathogenic agents out of the gut and into the brain. One study demonstrated that butyrate‐producing bacteria enhance intestinal epithelial barrier integrity and their absence can contribute to barrier dysfunction . Others found more Heliobacter pylori in the sera and gut mucosa of AD patients compared with controls .…”